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The molecular hallmarks of adultT cell leukemia (ATL) comprise outstanding deregulations
of signaling pathways that control the cell cycle, resistance to apoptosis, and proliferation
of leukemic cells, all of which have been identified by early excellent studies. Neverthe-
less, we are now confronted the therapeutic difficulties of ATL that is a most aggressive
T cell leukemia/lymphoma. Using next-generation strategies, emerging molecular charac-
teristics such as specific surface markers and an additional catalog of signals affecting the
fate of leukemic cells have been added to the molecular hallmarks that constitute an orga-
nizing principle for rationalizing the complexities of ATL. Although human T cell leukemia
virus type 1 is undoubtedly involved in ATL leukemogenesis, most leukemic cells do not
express the viral protein Tax. Instead, cellular gene expression changes dominate home-
ostasis disorders of infected cells and characteristics of ATL. In this review, we summarize
the state of the art of ATL molecular pathology, which supports the biological properties of
leukemic cells. In addition, we discuss the recent discovery of two molecular hallmarks of
potential generality; an abnormal microRNA pattern and epigenetic reprogramming, which
strongly involve the imbalance of the molecular network of lymphocytes. Global analyses
of ATL have revealed the functional impact of crosstalk between multifunctional pathways.
Clinical and biological studies on signaling inhibitory agents have also revealed novel onco-
genic drivers that can be targeted in future. ATL cells, by deregulation of such pathways
and their interconnections, may become masters of their own destinies. Recognizing and
understanding of the widespread molecular applicability of these concepts will increasingly
affect the development of novel strategies for treating ATL.
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INTRODUCTION: CURRENT STATUS OF ADULT T CELL
LEUKEMIA RESEARCH
Adult T cell leukemia (ATL), which is derived from human T
cell leukemia virus type 1 (HTLV-1)-infected CD4+ T cells, is an
aggressive T cell leukemia/lymphoma with the worst poor prog-
nosis (Yamaguchi and Watanabe, 2002). Endemic expansion of
HTLV-1 infection and related ATL onset have been observed in
Japan (Iwanaga et al., 2010). The diverse clinical features of ATL
have led to its sub-classification into acute, lymphoma, chronic,
and smoldering subtypes. ATL has a poor prognosis with a mean
survival time of 13 months and is refractory to currently available
combination chemotherapy (Yamada et al., 2001). It is therefore
essential to develop a novel treatment strategy, in particular, a
molecular targeting therapy. ATL is incurable because we do not
have complete understanding of its molecular basis, leading to
the lack of molecular targeting. Although HTLV-1 is an apparent
causative agent of ATL, several studies have demonstrated that viral
gene expression is rare, except for the expression of the HTLV-1
antisense gene product HBZ (Gaudray et al., 2002). Mounting evi-
dence has shown that ATL does not contain the somatic mutant
genes that can explain its aggressiveness. However, it is evident
that ATL cells possess multiple deregulations of genome and gene
regulation, namely the molecular hallmarks of ATL, which should
be targeted (Figure 1). We believe that normal cells acquire a suc-
cession of molecular hallmarks as they progressively evolve into a
neoplastic state and that the multistep process of human patho-
genesis can be rationalized by the need of incipient cancer cells
for acquiring traits that enable them to become leukemogenic and
ultimately malignant. In this review,we first summarize the essence
of each molecular hallmarks of ATL cells. Basic molecular analyses
and next-generation global analyses of ATL samples have revealed
the molecular traits of ATL. We address new developments that
broaden the scope of the conceptualization and describe recent
advances of science to acquisition of the molecular mechanis-
tic underpinnings. Finally, we discuss the possibility and future
direction of treating ATL.
MOLECULAR HALLMARKS CONTROLLED BY TAX AND HBZ
Since 1985, numerous excellent studies have indentified signal-
ing abnormalities in HTLV-1-associated cells, mainly induced by
HTLV-1 Tax. In general, T cell disorders include several deregula-
tions of cellular processes that regulates the cell cycle, cell prolif-
eration, and cell survival. Tax has been shown to disrupt all these
cellular processes. The classical oncogenic function of Tax was first
demonstrated in a study of cell cycle regulation. Tax was found
to inhibit the cyclin-dependent kinase (CDK) inhibitor (CKI)
CDKN2A (p16INK4A) by physical interaction (Suzuki et al., 1996).
Several subsequent studies also revealed the mitogenic activity
of Tax exerted through the stimulation of G1 to S phase tran-
sition (Akagi et al., 1996; Neuveut et al., 1998; Schmitt et al., 1998;
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FIGURE 1 |Transition from HTLV-1-infected cell to transformed leukemic
cell. In early and latent clinical phases, the HTLV-1 Tax and HBZ mainly act as
driving forces for the molecular hallmarks of infected cells. After a long-term
latency, leukemic cells have acquired genetic and epigenetic abnormalities,
which lead to deregulations of gene expression pattern, cell cycling, signaling
activation, and miRNA expression. These molecular changes consequently
induce cellular hallmark capabilities of ATL such as chronic proliferation,
apoptotic resistance, multiple organ invasion, and drug resistance.
Suzuki et al., 1999; Iwanaga et al., 2001; Haller et al., 2002; Liang
et al., 2002). Tax also affects a cohort of cell cycle-related proteins,
including CDKs, CDKN1A, CDKN1B, and CDKN2A, by regulat-
ing their expression or by physical interaction. Tax also participates
in genetic damage (Jeang et al., 1990; Ressler et al., 1997; Kao and
Marriott, 1999). Because of particular functions of Tax that can
interact with many host factors (Interactome; Boxus et al., 2008;
Simonis et al., 2012), Tax can activate several signaling pathways
and lead to abnormal gene expression (a Tax-dependent molecu-
lar hallmark) and overproduction of several cytokines. Especially,
IL-2 and its receptor are important for T cell activation. IL-2 sig-
nals through its receptor are primarily delivered by two molecular
families, the Janus tyrosine kinases (JAKs) and signal transduc-
ers and activators of transcription (STATs), whose activation leads
to lymphocyte proliferation. Tax can also activate the NF-κB and
NFAT pathways responsible for the predominant expression of IL-
2 and the IL-2 receptor (Ballard et al., 1988; Ruben et al., 1988;
Hoyos et al., 1989; McGuire et al., 1993; Good et al., 1996). These
findings implicate the IL-2–IL-2 receptor autocrine loop in ATL;
however, several studies have shown that alterations of the loop
alone are not sufficient to ensure the maintenance and prolifera-
tion of ATL cells because most Tax- or HTLV-1-immortalized T
cells still require exogenous IL-2 and do not express detectable
amounts of either IL-2 mRNA or protein (Akagi and Shimo-
tohno, 1993; Chung et al., 2003; Chen et al., 2010). Similarly, IL-15
and its receptor and IL-13 and its receptor have been associated
with Tax-expressing cells because similar to IL-2, they activate the
STAT pathways (Azimi et al., 1999; Mariner et al., 2001; Chung
et al., 2003; Wäldele et al., 2004). IL-6 is also transduced by Tax
through the NF-κB pathway (Villiger et al., 1991; Muraoka et al.,
1993). Because IL-6 mainly participates in inflammatory signaling,
HTLV-1 infection can induce cytokine-dependent inflammation,
which is frequently observed in ATL as well as HTLV-1-associated
myelopathy/Tropical spastic paraparesis (HAM/TSP; Oh et al.,
2011). OX40, a member of the TNF-receptor superfamily, is
specifically expressed in HTLV-1-infected cells, whose expression
is induced by the Tax-NF-κB pathway. Tax may play a role in
leukemic cell infiltration in addition to cell adhesion in vivo (Imura
et al., 1997). Tax affects not only the abovementioned signaling
pathways but also the TGF-β pathway (Kim et al., 1990; Höllsberg
et al., 1994; Arnulf et al., 2002; Lee et al., 2002). It has been recently
shown that TGF-β signaling is activated by HBZ by binding with
Smad 2/3 (Zhao et al., 2011). TP53 is the master regulator of the
cell cycle that guards against DNA damage by inducing the tran-
scription of several genes. Tax can inhibit TP53 functioning in
multiple ways (Grassmann et al., 2005).
Strong NF-κB activation is the outstanding hallmark provided
by Tax. NF-κB represents a family of inducible transcription
factors that regulate diverse biological processes, including the
growth and survival of both T cells and non-lymphoid cells.
Transcriptional activation of genes such as several cytokines and
apoptosis-resistance factors plays an important role in immu-
nity. Tax acts as an intracellular stimulator of IKK by physical
interaction, leading to persistent activation of NF-κB-mediated
transcription. The Tax/IKK complex formation relies on the phys-
ical interaction between Tax and the IKK regulatory subunit IKKγ.
The Tax/IKKγ interaction is required for recruiting Tax to the IKK
catalytic subunits and for Tax-mediated IKK activation (Sun and
Yamaoka, 2005). Recent studies have identified cellular proteins
that are important for Tax-mediated NF-κB activation, such as
NRP/Optineurin and TAX1BP1 (Journo et al., 2009; Shembade
et al., 2011), and the ubiquitin-specific peptidase USP20 (Yasunaga
et al., 2011). Subcellular localization of Tax also predominantly
controls Tax-mediated NF-κB activation (Fryrear et al., 2009).
Given that NF-κB governs the expression of a large array of cellu-
lar genes that control various cellular functions, the phenotypes of
HTLV-1-infected cells are dominated by Tax-mediated abnormal
activation.
Tax also activates several signaling pathways through key tran-
scriptional factors such as CREB,SRF,and AP-1. It does not directly
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bind to promoter or enhancer DNA, however, disruption of these
pathways causes serious gene expression disorders (Grassmann
et al., 2005).
It should be also noted that HTLV-1 antisense product HBZ
seems to be involved in leukemogenesis; its expression is sustained
in leukemic cells. In vitro and in vivo studies have demonstrated
that the growth-promoting activity of HBZ RNA may play an
important role in oncogenesis by HTLV-I (Satou et al., 2006).
Furthermore, transgenic expression of HBZ in CD4+ T cells
induces T cell lymphomas and systemic inflammation in mice.
HBZ directly induces Foxp3 gene transcription, and the increased
CD4+Foxp3+ Treg cells in HBZ transgenic mice are function-
ally impaired, suggesting that the expression of HBZ in CD4+ T
cells may be a key mechanism of HTLV-1-induced neoplastic and
inflammatory diseases (Satou et al., 2011).
Taking together with these mounting evidences, Tax and HBZ
undoubtedly contribute to leukemogenesis in HTLV-1-infected
T cells. However, as a low rate of incidence, clinical observa-
tion implies that HTLV-1 itself does not have a strong capacity
of leukemogenesis in contrast with other animal leukemia viruses.
CHROMOSOMAL CHANGES AND GENE ALTERATIONS IN ATL
Tax is not expressed in most ATL cases because HTLV-1 provirus is
substantially silenced by proviral defect and/or epigenetic mech-
anism (Tamiya et al., 1996; Koiwa et al., 2002; Taniguchi et al.,
2005). However, leukemic cells possess very similar traits to Tax-
expressing cells (Figure 1). The paradoxical truth, i.e., memory of
Tax, still remains to be elucidated. Investigation of established ATL
cell lines and primary ATL samples has led to the identification of
the molecular hallmarks of leukemic cells, which may partially
explain their malignant characteristics.
From 1980s, chromosomal analyses of clinical cases were
reported. Therefore, we know that ATL is characterized by various
abnormal chromosomes. Kamada et al. (1992) reported that 96%
of ATL cases had an abnormal chromosome pattern, suggesting
that a genomic catastrophe underlies the clinical and molecular
characteristics of ATL, which is consistent with all other cancers.
In 2000s, global analysis has been available and whole genomic
analysis could be challenged. Comparative genomic hybridization
(CGH) revealed the genomic distinctions between the clinical sub-
types; patients with aggressive ATL (acute and lymphoma) have
a higher number of chromosomal imbalances, losses, and gains
than those with indolent ATL (chronic and smoldering). Thus,
genomic abnormalities are prognostic factors (Tsukasaki et al.,
2001a). High-resolution analyses based on microarrays unveiled
the genomic properties of ATL (Oshiro et al., 2006) and shed
light on the genomic characteristics that affect the gene expression
pattern (Figure 2).
In cancer cells, genetic mutations and deletions are generally
observed in genes important for cell cycle regulation, cell survival,
and cell proliferation. In ATL, the accumulation of genetic dele-
tions in the gene encoding the cell cycle regulator CDKN2A have
been reported (Hatta et al., 1995; Uchida et al., 1996). South-
ern blotting analyses of samples from large cohort studies (114
patients) also demonstrated that theCDKN2 family (p15 and p16)
is lost in more frequently observed in the acute type (33.8%) than
in the chronic type of ATL (5.4%; Yamada et al., 1997). Patients
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FIGURE 2 | Acquired molecular hallmarks of ATL. From the beginning of
ATL discovery, indicated molecular hallmarks have been suggested.
Hierarchical regulation of the gene expression has been expected.
Abnormal expressions of these cytokines and receptors as well as various
proteins that act as anti-apoptotic factors or proliferation agents are
responsible for the malignant phenotypes as hallmark capabilities.
with these genetic deletions showed reduced survival compared
with those without deletions. CDKN2A transcription is also reg-
ulated in an epigenetic manner. Abnormal DNA methylation has
been during ATL progression (Nosaka et al., 2000).
Alterations of other cell cycle-regulating genes are unusual.
Mutations of CDKN1B (p27Kip1) is rare in non-Hodgkin’s lym-
phoma and ATL (Morosetti et al., 1995). Mutations ofRb gene have
also been observed in a few ATL patients (Hatta et al., 1997). Exten-
sive analyses have revealed that 26–40% of ATL cases have a p53
gene mutation, which is much less than that observed in other can-
cers (Nagai et al., 1991; Cesarman et al., 1992; Sakashita et al., 1992;
Nishimura et al., 1995). Gene expression analysis of ATL samples
showed that CDKN1A (p21Cip1) is commonly down regulated in
ATL (Watanabe et al., 2010). In contrast, Tax activates p21Cip1
expression in HTLV-1-infected cells, which may be an important
mechanism for stopping the host at the G1/S boundary and repair-
ing damaged DNA before entering the S phase entry (Cereseto
et al., 1996; de La Fuente et al., 2000). Although p21Cip1 transcrip-
tion may be activated by the Tax–CREB pathway in infected cells,
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it seems to be epigenetically silenced in several cancers, including
ATL. Thus, these gene alterations and related expression patterns
are important molecular hallmarks of ATL as well as other can-
cers. Of note, no ATL cell has been shown to have both mutations,
suggesting that either p16 or p53 mutation may be sufficient to
promote the more aggressive phenotype of leukemic cells (Tawara
et al., 2006). In addition, as many ATL patients carry a wild-type
p53, TP53 activation by antagonists such as Nutlin-3a may be a
promising strategy for ATL therapy (Hasegawa et al., 2009). The
ability to resist apoptotic cell death is conferred by Fas gene muta-
tion (Tamiya et al., 1998; Maeda et al., 1999). Indeed, Fas-negative
ATL cells are resistant to adriamycin-induced apoptosis in vitro,
which is consistent with the finding that ATL in this case is resistant
to chemotherapy.
Single nucleotide polymorphism (SNP) is another possible
cause for developing ATL. TNF-α polymorphism may be asso-
ciated with increased susceptibility to development of ATL in
HTLV-1 carriers (Tsukasaki et al., 2001b). An immunological study
also suggested that the HLA haplotype is related to ATL progres-
sion (Yashiki et al., 2001). Currently, whole SNP can be detected
by next-generation sequencing and other array-based techniques.
Global understanding of SNPs in ATL patients may provide us
with the genetic basis of the familial clustering of ATL.
By utilizing global survey techniques for analyzing the gene
copy number, several research groups have detected specific gene
copy number patterns in ATL. CGH methods first demonstrated
gains at 14q32 and 2p16-22 in ATL cell lines (Ariyama et al.,
1999). Fluorescence in situ hybridization (FISH) analysis with
several yeast artificial chromosome (YAC), BAC, and PAC clones
also mapped the breakpoints in ATL cell lines with 6q aberrations
(Tagawa et al., 2002). Clinical subtype-specific genomic alterations
in aggressive ATL were also identified by array-based CGH (Oshiro
et al., 2006). The lymphoma type of ATL had significantly more fre-
quent gains at 1q, 2p, 4q, 7p, and 7q and losses at 10p, 13q, 16q, and
18p, whereas the acute type showed a gain of 3/3p.CARMA1 is also
a possible target gene for 7p22 amplification in the lymphoma type
but not in the acute type of ATL. In contrast, BCL11B is expressed
in the acute type of ATL, regardless of 14q32 gain/amplification;
however, there is no or low expression of the gene in the lym-
phoma type of ATL. Taken together, these findings suggest that the
acute and lymphoma types of ATL are genomically distinct. The
physiological molecular hallmarks of ATL have been identified by
integrating the gene copy number and gene expression analyses
findings, and these are described below.
GLOBAL GENE EXPRESSION ANALYSES OF ATL
Genetic alterations and other modulations enhance specific gene
expression signatures. Classically, based on a comparison between
normal T cells and ATL cell lines as well as primary leukemic
cells, ATL has been shown to have a distinct gene expression pat-
tern that may reflect its clinical pathogenesis. In addition, global
expression analyses, mainly based on microarray, have identified
emerging molecular hallmarks that can possibly be targeted in ATL
therapies.
First, Harhaj et al. (1999) performed gene array analysis of
HTLV-1-immortalized cells and reported up- and downregulated
genes. Ruckes et al. (2001) performed suppressive subtractive
hybridization that enabled the isolation of novel sequences derived
from unknown genes. They identified a number of genes linked
to Tax transformation and ATL leukemogenesis. Systematic com-
parison of gene expression between cultured cells from patients
with acute ATL and that of stimulated peripheral T lymphocytes
revealed 346 cDNA clones, which included the genes encoding
IL-2 receptor α chain and p21Cip1. They also included a dual-
specific protein phosphatase (PAC1), an interferon-inducible fac-
tor (ISG15),a basic helix–loop–helix transcription factor (DEC-1),
and the secreted anti-apoptotic chemokine I-309. Pise-Masison
et al. (2002) also reported the results of analyses performed using
an Affymetrix Hu6800 GeneChip. They identified 763 genes with
differentially regulated expression in HTLV-1 cell lines.
Tsukasaki et al. (2004) directly analyzed the gene expression
patterns of fresh ATL samples (three acute types and one chronic
type) using high-density oligonucleotide DNA arrays. A total of
203 genes that included ribosomal proteins, proteasome subunits,
translation factors, immunophilins, heat shock proteins, and genes
important for DNA replication were found to be upregulated in
ATL cases, and 91 genes were downregulated. Sasaki et al. (2005)
also determined the expression profiles of more than 12,000 genes
in eight cases of the acute type of ATL using microarray analysis,
and they found that 192 genes were upregulated more than twofold
compared with healthy CD4+ and CD4+/CD45RO+ T cells. In
particular, the expression of tumor suppressor in lung cancer 1
(TSLC1), caveolin 1, and prostaglandin D2 synthase was increased
by more than 30-fold. Interestingly, comparison of gene expression
between established cell lines with or without HTLV-1 infection
led to the identification of the specific HTLV-1-related cell surface
marker CD70, which is also expressed in freshly isolated leukemic
cells (Baba et al., 2008).
Integrated analyses of the genome and its expression revealed
more detailed data for the acquisition of molecular and physiologi-
cal information. Choi et al. (2007) isolated CD4+T cells from ATL
patients and profiled their gene expression using DNA microarrays
containing>44,000 probe sets. Changes in the chromosomal copy
number were examined for 24 cell specimens using microarrays
harboring approximately 50,000 probe sets. Coordinated analysis
revealed a novel molecular target, the HGF–MET pathway. Liga-
tion of MET by increased plasma HGF levels may confer a growth
advantage on ATL cells through the phosphatidylinositol 3-kinase
(PI3K) and Ras pathways.
We performed further global integrated analyses of sam-
ples from ATL patients using mRNA expression array (n= 52),
microRNA (miRNA) microarray (n= 40), and DNA copy number
analysis using SNP-based array (n= 168; Yamagishi et al., 2012).
Each analysis revealed many novel molecular characteristics of
ATL (data available in the Gene Expression Omnibus database).
Analysis of this massive dataset derived from primary ATL samples
led to the conclusion that genetic and epigenetic imbalances are
involved in ATL leukemogenesis through miRNA and the signaling
pathways responsible for leukemic cell survival, proliferation, and
invasiveness. Taken together, these findings clearly indicate that
disrupted gene expression is a molecular hallmark of ATL. Diverse
abnormalities have been found in each of these comprehensive
studies; however, several gene alterations and other critical events
have been commonly implicated as determinants of the gene
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expression pattern. Abnormal expression of different cytokines,
their receptors, and various proteins that act as anti-apoptotic
factors or proliferation agents is responsible for malignant phe-
notypes as hallmark capabilities (Figure 2). From the spreading
intelligence, we have to acquire the genuine molecular targets
harboring in the bare bones of ATL.
SIGNALING NETWORKS IN ATL: MAIN DRIVING FORCES
The cellular complexity of signaling networks confers robustness
to specific gene expression and biological functions. This is sup-
ported by the fact that the inhibition of a signaling pathway can
strictly suppress abnormal gene expression. The functional char-
acteristics of ATL cells, such as chronic proliferation, abnormal
survival, and penetrating multiple organs, is supported by aberrant
gene expression, as described above.
Activation of NF-κB signaling is the most outstanding hall-
mark of both HTLV-1-infected cells and leukemic cells. Abnormal
activation and deficient negative control of the NF-κB pathway
strongly contributes to prolonged survival, proliferation, and inva-
siveness, all of which are observed in ATL cells. Ruben et al. (1988)
found that Tax can activate IL-2 receptor gene expression in a
NF-κB-dependent manner. Following this, several studies clearly
demonstrated that Tax can activate NF-κB activity through a mul-
tistep (Sun andYamaoka,2005). Strong and persistent activation of
NF-κB signaling was then demonstrated in leukemic cell lines that
did not express Tax (Mori et al., 1999). In transformed ATL cells,
both the canonical and non-canonical NF-κB pathways are persis-
tently activated because NF-κB inducing kinase (NIK) is aberrantly
expressed in ATL (Saitoh et al., 2008). NIK plays a central role in
non-canonical NF-κB signaling by IKKα phosphorylation (Thu
and Richmond, 2010). Very recently, we found a novel linkage
between NF-κB activation and miRNA deregulation. Comprehen-
sive gene expression analysis and in vitro experiments revealed
that miRNA-31 (miR-31) can regulate NIK expression through
the 3′ untranslated region (UTR). In ATL cells, miR-31 expression
is genetically and epigenetically silenced, which in turn induces
constitutive NF-κB activation through NIK expression (Figure 3;
Yamagishi et al., 2012). Because current evidence clearly indicates
that miR-31 dominates NF-κB activity in T cells, manipulating cel-
lular miR-31 levels may be a novel molecular approach to reduce
NF-κB activity and induce apoptosis.
Numerous efforts have demonstrated that NF-κB inhibitory
agents may be suitable for treating ATL. Inhibitors such as borte-
zomib (Satou et al., 2004), Bay 11-7082 (Mori et al., 2002),
DHMEQ (Watanabe et al., 2005), ACHP (Sanda et al., 2006), and
IMD0354 (Uota et al., 2012) have the ability to kill leukemic cells.
Fludarabine, a purine analog that has significant activity in B cell
malignancies, also inhibits the NF-κB activity in ATL (Nishioka
et al., 2007). Tax degradation by arsenic trioxide and IFN-α treat-
ments is also useful for inhibiting NF-κB in HTLV-1-infected cells
(El-Sabban et al., 2000). In the near future, gene manipulation
for example by siRNA targeting NIK may be a promising strat-
egy for inhibiting NF-κB activity with strict specificity (Yamagishi
et al., 2012). Because NF-κB prevention showed good results in a
xenograft model of cell lines with or without Tax (Dewan et al.,
2003; Watanabe et al., 2005; Ohsugi et al., 2007a), molecular target-
ing therapy based on the NF-κB pathway is a promising new ATL
treatment. Of note, NF-κB inhibition by DHMEQ can also remove
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FIGURE 3 | NF-κB signaling pathway in ATL. Compared to normal T
cell, HTLV-1-infected cell shows intense activity of NF-κB pathway
through the Tax interactome. In contrast, leukemic cell sustains
strong NF-κB activity without Tax by acquisition of miR-31-dependent
NIK expression. Activation of the non-canonical pathway ultimately
joins canonical pathway, resulting in transactivation of numerous
target genes important for cell survival, cytokine production, and
invasiveness.
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virus-carrying cells from carrier peripheral blood mononuclear
cell (PBMC) samples (Watanabe et al., 2005).
Why is NF-κB important for ATL cell survival? One of the target
genes is BCL-XL, which is expressed when NF-κB is stimulated. In
HTLV-1-infected cell lines, BCL-XL is expressed through the Tax-
NF-κB pathway. Interestingly, fresh ATL samples show BCL-XL
overexpression (Nicot et al., 2000). Given that BCL-XL is a prin-
cipal anti-apoptotic protein as a BCL-2 family member, persistent
BCL-XL expression is one of the molecular capability of apop-
totic resistance, which may contribute to clinical chemoresistance.
Indeed, inhibition of the NF-κB pathway by NIK depletion leads
to impaired BCL-XL levels and apoptotic cell death in ATL (Yam-
agishi et al., 2012). In addition, a recent study has implicated that
both BFL1 (BCL2A1) and BCL-XL are responsible for ATL cell
survival. BFL1 expression is regulated by Tax and HBZ through
the NF-κB and AP-1 pathways, respectively (Macaire et al., 2012).
The JAK–STAT pathway, which is universal and essential to
cytokine receptor signaling, is also one of the best understood
signal transduction cascades in several cell types, including ATL
cells. The JAK–STAT pathway mediates signaling by cytokines,
which control cell survival, proliferation, and differentiation. Con-
stitutive JAK activation leads to persistent activation of STAT
transcription factors, and several cancers exhibit constitutive STAT
activation in the absence of JAK- or STAT-activating mutations.
JAK–STAT activation in HTLV-1-infected cells was first reported
in 1995 (Migone et al., 1995). Takemoto et al. (1997) demonstrated
that STAT-3 and STAT5 are activated in freshly isolated ATL cells.
However, functional redundancy was also reported. Blockade of
the JAK3–STAT5 pathway by AG490 failed to inhibit the prolifera-
tion of HTLV-1-transformed T cell lines, despite activation of the
pathway (Kirken et al., 2000). Recently, a JAK2–STAT5 inhibitor,
AZ960, was shown to have an anti-proliferative effect on HTLV-
1-infected and ATL cell lines (Yang et al., 2010). However, which
gene is transactivated by STAT remains unknown. The biolog-
ical relevance of the JAK–STAT pathway in ATL remains to be
elucidated.
EMERGING SIGNALING PATHWAYS AND INHIBITORY
AGENTS
In addition to the abovementioned pathways, several signaling
pathways, including the AP-1, NFAT, and CREB pathways, may be
involved in the functional characteristics of ATL (Hall and Fujii,
2005). These are activated by Tax. Leukemic cells may have certain
activities in each of these pathways.
The RhoA family also participates in Tax-mediated immortal-
ization. A recent study employing a proteomic approach to identify
Tax-binding proteins in a HTLV-1-infected T cell line identified
direct interactions between Tax and several small GTPases, includ-
ing RhoA, Rac1, and Cdc42, all of which are involved in a wide vari-
ety of cellular processes, including cytoskeleton organization and
transcriptional activation (Wu et al., 2004). Recently, our global
gene expression analysis as well as miRNA study strongly suggested
that RhoA is overexpressed in ATL cells. A decreased miR-31 level
may contribute to RhoA expression and migration activity (Yam-
agishi et al., 2012). The gene expression signature determined from
patient samples could identify the additional signaling pathways
involved in leukemogenesis (authors’ unpublished data).
Recently, several studies have demonstrated that ATL shows
emerging signaling activation, which is well established as onco-
genic signaling in other types of cancer. Typically, the Notch
pathway, which is the signaling pathway implicated in T cell
acute lymphoblastic leukemia (T-ALL), is also activated in ATL
(Pancewicz et al., 2010). More than 30% of ATL cases show acti-
vating mutations in NOTCH1, leading to reduced CDC4/Fbw7-
mediated degradation and stabilization of the intracellular cleaved
form of Notch1 (ICN1). Inhibition of Notch signaling by a γ-
secretase inhibitor reduced tumor cell proliferation and tumor
formation in ATL-engrafted mice. It is therefore suggested that
activated Notch may be important for ATL pathogenesis.
TGF-β signaling is also reportedly important. Increased TGF-β
production was observed in freshly isolated ATL cells, and this was
at least partially mediated by AP-1 (Niitsu et al., 1988; Kim et al.,
1990). Nevertheless TGF-β could inhibit the growth of normal T
lymphocytes, HTLV-1-infected cells were resistant to this inhibi-
tion (Höllsberg et al., 1994). In ATL cells, transcription factor 8
(TCF8) is frequently disrupted by several mechanisms, primarily
by epigenetic dysregulation. TCF8 mutant mice frequently develop
invasive CD4+T cell lymphomas in vivo. Downregulation of TCF8
expression in ATL cells in vitro is associated with resistance to TGF-
β1, suggesting that escape from TGF-β1-mediated growth inhibi-
tion is important in the pathogenesis of ATL (Hidaka et al., 2008).
The same research group also reported that ZEB1 downregulation
and Smad7 overexpression contribute to resistance to TGF-β1-
mediated growth suppression in ATL (Nakahata et al., 2010). ZEB1
plays a critical role in regulating the epithelial–mesenchymal tran-
sition (EMT) in several solid cancers. The general function of ZEB1
in lymphocytes, particularly in association with leukemogenesis
and TGF-β signaling, is a very intriguing issue.
If a chemical drug that can inhibit cellular signaling can induce
apoptosis specifically, it is probable that leukemic cell survival is
supported by the targeted signaling. Recent studies of inhibitors
have indicated that mTOR signaling may be involved in ATL.
mTOR is a serine/threonine-specific protein kinase that is located
downstream of the PI3K/Akt pathway. Deregulation of mTOR
signaling is implicated in a range of cancers due to its roles in
cell survival and proliferation, protein synthesis and breakdown,
membrane trafficking,and protein kinase C signaling (Zoncu et al.,
2011). Ikezoe et al. (2007) used several inhibitors to show that the
PI3K/Akt/mTOR pathway is activated in ATL cell lines as well
as fresh ATL cells. In addition, a resent study reported that the
mTOR complex 1 (mTORC1) inhibitor everolimus has a dramatic
inhibitory effect on the growth of HTLV-1-positive and HTLV-1-
negative malignant T cells, whereas normal resting or activated
T cells are resistant to it (Darwiche et al., 2011). Furthermore, in
addition to HTLV-1-infected cells in which Tax activates the Akt
pathway (Liu et al., 2001), transformed leukemic cells in which Tax
is not expressed may have some Akt activity. The most important
point is how these pathways are constitutively activated in ATL.
The functional importance of this pathway and its therapeutic
potential will be addressed in the near future.
In the context of inhibitory agents, a higher response rate
following azidothymidine/interferon α (AZT/IFNα) treatment of
ATL patients has been reported in several human trials (Gill et al.,
1995; Bazarbachi et al., 2010). AZT treatment of ATL patients
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inhibits telomerase activity and results in progressive telomere
shortening and increased p14ARF expression. A functional rela-
tionship between p53 and sensitivity to AZT has also been sug-
gested (Datta et al., 2006). Ritonavir, developed as a protease
against HIV-1, also has an anti-ATL effect. Ritonavir decreases NF-
κB activity linked to the inhibition of IκBα phosphorylation and
induces the apoptosis of ATL cells. In addition, it very efficiently
prevents tumor growth and leukemic infiltration in various organs
of NOG mice when administered at the same dose as that used in
the treatment of patients with AIDS (Dewan et al., 2006). Together,
several signaling networks are deregulated in leukemic cells, and
these are a specific molecular feature of ATL (Figure 2). At present,
signal interception is the most effective strategy to treat ATL. At
the same time, the occurrence of incidental side effects should be
carefully considered because these signaling pathways are essential
for normal cell function and survival.
CYTOKINES PRODUCTION AND ATL
CD4+ T cells play a central role in the immune response by con-
trolling cells such as B cells, dendritic cells, and cytotoxic cells
and their responses through various cytokines. Deregulation of
the associated signaling pathways leads to abnormal gene expres-
sions, including that of several cytokines. ATL has been implicated
in the production of various cytokines, including IL-1 (Wano
et al., 1987), TGF-β (Niitsu et al., 1988), TNF-α, IFN-γ, GM-CSF
(Yamada et al., 1996), and PTHrP (Watanabe et al., 1990). Espe-
cially, an elevated serum C-terminal PTHrP level is a characteristic
marker of the HTLV-1 carrier status, and the determination of
this level in ATL patients could be useful for assessing the prog-
nosis (Yamaguchi et al., 1994). SCID mice model of ATL also
showed clearly elevated serum levels of calcium and C-terminal
PTHrP, resulting in the development of hypercalcemia (Takaori-
Kondo et al., 1998). The high frequency of hypercalcemia is one
of the notable clinical characteristics of ATL, in particular, the
aggressive types of ATL (Kiyokawa et al., 1987). Besides PTHrP,
which plays an important role in bone resorption by stimulating
osteoclasts, abnormal expression of the RANK ligand (RANKL)
has also been demonstrated in ATL with hypercalcemia (Nosaka
et al., 2002). Recent studies have revealed that a central region of
HTLV-1 gp46 acts as an antagonist for osteoprotegerin and leads
to hypercalcemia (Sagara et al., 2007, 2009).
SCID mice engrafted with cells from Tax-transgenic mice that
develop lymphoma produced TNF-α, PDGF-BB, sICAM-1, and
sVCAM-1 as factors that may contribute to high levels of organ
infiltration (Watters et al., 2010). PDGF, in particular, the BB iso-
form, is a well-known potent osteotropic factor that stimulates
the osteoclasts and osteoblasts functions (Yi et al., 2002). High
IL-2 production was not observed in previous ATL studies or in
our microarray data (Yamagishi et al., 2012). Nevertheless, IL-2 is
an HTLV-1-induced cytokine associated with the NF-κB pathway
(Hoyos et al., 1989). In contrast, receptor subsets for IL-2 (IL2Rs)
are generally overexpressed in ATL cells.
Interestingly, smoldering/chronic ATL PBMCs spontaneously
proliferate ex vivo in an IL-12-, IL-9-, and IL-15-dependent
manner, whereas acute type ATL PBMCs do not proliferate
or proliferate independent of cytokines. Furthermore, purified
leukemic cells from indolent ATL cases produce IL-2/IL-9
and the downstream JAK–STAT pathway is activated. Thus,
autocrine/paracrine cytokine stimulation of leukemic cell prolif-
eration may occur in patients with smoldering/chronic ATL (Chen
et al., 2010).
CELL SURFACE MARKERS AND THEIR FUNCTIONS
IL-2 receptor α (CD25) was the first marker of ATL and HTLV-1-
infected cells. CD25 expression is dependent on NF-κB activity
(Ruben et al., 1988). Global gene expression analysis has also
validated the high CD25 mRNA level in ATL patient samples
(Yamagishi et al., 2012).
Chemokines and their receptors mainly function in the migra-
tion and tissue localization of lymphocytes. The expression of
the following ATL-specific chemokine receptors has been identi-
fied: CCR4 (Yoshie et al., 2002), CCR7 (Hasegawa et al., 2000),
CCR8 (Ruckes et al., 2001), and CXCR4 (Twizere et al., 2007). In
addition, other cell surface proteins such as OX40 (Imura et al.,
1997) and TSLC1 (Sasaki et al., 2005) are highly expressed in
ATL cells and are thus the molecular hallmarks of ATL; they may
also participate in leukemogenesis. For example, TSLC1, a well-
known tumor suppressor in various carcinomas, is overexpressed
in ATL. The cytoplasmic domain of TSLC1 directly interacts with
the PDZ domain of TIAM1 and induces the formation of lamel-
lipodia through Rac activation in HTLV-1-transformed and ATL
cell lines. TIAM1 may integrate signals from TSLC1 to regulate the
actin cytoskeleton through Rac activation (Masuda et al., 2010).
Some ligands are also expressed by ATL cells; therefore,
autocrine/paracrine stimulation is implicated. Tax develops a
strategy based on the activation of the SDF-1α/CXCR4 axis
in infected cells (Twizere et al., 2007). In Tax-transgenic mice
and their transplantation model, AMD3100, a CXCR4 antago-
nist, inhibits the infiltration of lymphomatous cells into tissues
in vivo, indicating the involvement of the SDF-1α/CXCR4 inter-
action in leukemic cell migration (Kawaguchi et al., 2009). CCR4
expression is clinically considerable. The defucosylated anti-CCR4
monoclonal antibody KW-0761 induces CCR4-specific antibody-
dependent cellular cytotoxicity (ADCC) against CCR4-positive
ATL cells. In view of its molecular functions, CCR4 expression
may also account for the frequent infiltration of ATL cells into the
skin and lymph nodes (Yoshie et al., 2002). Specific surface mark-
ers are therefore worthy of attention to identify concentrations of
leukemic cells as well as minor infected cells in asymptomatic car-
riers. A recent study reported the development of a new method for
concentrating leukemic cells by multi-color flow cytometry. The
majority of leukemic cells are included in the CD4+, CD3-dim,
and CD7-low subpopulations (Tian et al., 2011). Consequently,
characteristic expression of cytokines and their receptors is clearly
required for leukemic cell behavior, which in turn may be used as
landmarks and/or therapeutic motifs.
NEW PARADIGM FROM miRNA
According to the summary of previous ATL studies described
above, we can fight ATL to a certain extent. However, we cannot
cure ATL because of relapse with multidrug resistance, immun-
odeficiency, and strong invasiveness. In addition to the previously
proposed molecular hallmarks (Figure 2), we urgently need a con-
ceptual advance that can promote understanding of the source of
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disrupted gene expression. Indeed, in the course of our remark-
able progress in researching ATL and other malignancies, new
observations have helped in clarifying and modifying the original
formulations of the hallmark capabilities.
One of the most significant recent advances in biomedical
research has been the discovery of the 22-nt-long class of non-
coding RNA designated miRNA that posttranscriptionally regu-
lates gene expression by binding to the target mRNAs. miRNA is
expressed by all metazoans and plants, as well as by several DNA
viruses; it regulates cellular processes such as development, dif-
ferentiation, growth, homeostasis, stress responses, apoptosis, and
immune activation (Esquela-Kerscher and Slack, 2006). In ATL
filed, some studies have been reported, and several miRNA aber-
rations have been identified in HTLV-1-infected cells and ATL
samples.
Pichler et al. (2008) first identified abnormal miRNA expres-
sion in HTLV-1-infected cells. They explored the interconnections
between HTLV-1 and cellular miRNAs by using several HTLV-
1-transformed cell lines. miR-21, miR-24, miR-146a, and miR-
155 were found to be upregulated and miR-223 was found to
be deregulated in HTLV-1-infected cells. In particular, miR-146a
expression was directly stimulated by Tax through the NF-κB path-
way. In silico analysis predicts that many candidate genes may be
deregulated by miRNA changes (Pichler et al., 2008).
Yeung et al. (2008) performed miRNA microarray analysis of
327 well-characterized human miRNAs in 7 HTLV-1-related cell
lines and four acute ATL patient samples. They found that miR-
18a, miR-93, and miR-130b were overexpressed in ATL samples.
Of note, these miRNAs were also upregulated by PHA-mediated
T cell activation. Tumor protein p53 inducible nuclear protein 1
(TP53INP1) is a gene targeted by one of miR-93 and miR-130b,
and reduced TP53INP1 expression mediated by miRNA upregu-
lation contributes to cell proliferation and survival (Yeung et al.,
2008).
Bellon et al. (2009) also reported the result of miRNA array
analysis of 7 ATL samples and normal PBMC and CD4+T cells and
revealed that miR-150, miR-155, miR-223, miR-142-3p, and miR-
142-5p are upregulated, whereas miR-181a, miR-132, miR-125a,
and miR-146b are downregulated in ATL. They discussed that
miRNAs involved in normal hematopoiesis and immune responses
are profoundly deregulated in ATL tumor cells ex vivo (Bellon et al.,
2009).
Each of these studies has identified interesting miRNAs that
are deregulated in ATL-related cells; however, no identical miRNA
patterns have been observed. The amount of cellular miRNAs
may be susceptible to various environmental conditions such as
transcriptional activity, maturation processing, and epigenetic reg-
ulation. The end results appear to be affected by the methodology
employed and the conditions and types of samples used. Very
recently, we established global gene expression analyses of a large
cohort ATL study that included analyses of mRNA expressions,
miRNA levels, and genomic copy number (Yamagishi et al., 2012).
A strict threshold (p< 1× 10−5) and two-dimensional hierar-
chical clustering analysis revealed 61 miRNAs with significantly
altered expression levels in ATL cells (n= 40) compared with
control CD4+ T cells (n= 22). It is most important that pri-
mary ATL samples show global miRNA downregulation, similar to
observations in other cancer researches (Lu et al., 2005; Gaur et al.,
2007). Fifty-nine of the 61 miRNA (96.7%) showed decreased
expression in ATL. The amount of cellular miRNA may be sus-
ceptible to various environments such as transcriptional activity,
maturation processing, and also epigenetic regulation. Among
them, miR-31 is the most profoundly repressed miRNA in all
ATL individuals (fold change, 0.00403). It is a known tumor sup-
pressor that may also be associated with metastatic breast cancer
(Valastyan et al., 2009). Other downregulated miRNAs found in
ATL patients may also be involved in the hallmark capabilities of
ATL, since they are uniformly decreased in tested ATL samples and
each miRNA may regulate a large number of genes.
Several predictions and experimental approaches have defined
a novel miR-31 target gene, MAP3K14 (also called NIK), which is
a persistent NF-κB activator in various malignancies, including B
cell lymphoma (Pham et al., 2011), multiple myeloma (Annunzi-
ata et al., 2007), breast cancer (Yamamoto et al., 2010), pancreatic
cancer (Nishina et al., 2009), and ATL (Saitoh et al., 2008). Interest-
ingly, all these malignancies have low miR-31 levels. Manipulation
of the miR-31 level clearly indicated that the miR-31 level was
negatively correlated with cellular NF-κB activity. Importantly,
enforced miR-31 expression in B cells attenuated both BAFF and
CD40L-mediated NIK accumulation and subsequent canonical
and non-canonical NF-κB signaling. As discussed above, NF-κB
activity dominates the regulation of apoptosis and subsequent cell
survival. Induced miR-31 expression or NIK knockdown reduces
apoptotic resistant proteins such as BCL-XL and XIAP, result-
ing in strong apoptosis in ATL cell lines as well as in primary
leukemic cells from ATL patients (Yamagishi et al., 2012). Several
lines of evidence definitively support two notions: (1) miR-31 acts
as a tumor suppressor in T cells and (2) NIK-regulated NF-κB
is of pivotal importance to cancer cell survival (Uribesalgo et al.,
2012).
The fact that deregulated miRNA expression predominates NF-
κB activity is a conceptual advance. Regulation of global miRNA
downregulation and each regulatory network may shed light on
our understanding of the next-generation molecular hallmarks of
ATL and of molecules suitable for therapeutic targeting (Figure 4).
Since a single miRNA can regulate the expression of multiple genes,
pleiotropic miRNA may have potential as molecular therapy. Pro-
found miR-31 loss is a characteristic of ATL; however, decreased
miR-31 expression seems to be commonly observed in various
malignancies. The regulatory mechanism of miR-31 had not been
identified until our discovery. In general, down modulation of
gene expression is coordinated by some contents of transcriptional
factors and an epigenetic regulatory mechanism.
EPIGENETIC DEREGULATION OBSERVED IN ATL
Technological advances in genomics and epigenomics have sup-
plied new methods to distinguish one cell type from another. The
epigenetic code consists of the combined on–off states of hundreds
of genes, which coordinately dictate cellular identity and func-
tion. Increasing attention is being paid to global regulatory factors
and molecular mechanisms by which control gene transcription.
This genome programming operates fundamentally through DNA
methylation, histone chemical modification, and protein complex
binding in these environments.
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FIGURE 4 | Emerging molecular hallmarks, microRNA deregulation and
epigenetic reprogramming. An increasing body of research suggests that
two additional molecular hallmarks are involved in the pathogenesis of ATL. In
addition to the genomic abnormality, epigenetic imbalance widely governs the
downstream molecular capabilities. Deregulation of the cellular miRNA levels
directly influence hundreds of genes expression. Importantly, cross talking
among each category can attain more complex gene regulatory network that
is indispensable for exercise of various functions at appropriate timing.
Cancer-associated epigenetic reprogramming has been sug-
gested because DNA methylation is a transcriptional regulator.
In ATL, no attempt has been made to determine global epigenetic
statements that can explain deregulated gene expression. Analysis
of epigenetic factors such as DNA methylation and related gene
silencing has been reported, particularly in some tumor suppressor
genes such as the CDK inhibitor family.
The CpG island of CDKN2A gene is more frequently methy-
lated in fresh tumor cells isolated from patients with acute ATL
(47%) or lymphoma type ATL (73%) than in fresh tumor cells
isolated from patients with chronic (17%) and smoldering (17%)
ATL, which are relatively less malignant (Nosaka et al., 2000).
No CDKN2A gene is methylated in asymptomatic carriers or
uninfected individuals. A possible inverse correlation between
CDKN2A mRNA expression and gene methylation status is sug-
gested. Methylation-specific polymerase chain reaction (MSP)
also suggested the presence of an additional DNA methylation
in CDKN2B gene (20%; Hofmann et al., 2001). In addition to
the cell cycle regulators, multifunctional factors involved in cell
proliferation, differentiation, and apoptosis, e.g., bone morpho-
genetic protein (BMP) is deregulated by aberrant DNA methyla-
tion in malignant lymphomas (Daibata et al., 2007) and also ATL
(Taniguchi et al., 2008). Above all, the BMP6 promoter is hyperme-
thylated in ATL: acute (96%), lymphoma (94%), chronic (44%),
and smoldering (20%). BMP6 promoter methylation seems to be
a common epigenetic event at later stages of ATL. The adenoma-
tous polyposis coli (APC) gene is also a tumor suppressor, and its
mRNA level is at least partially regulated by DNA methylation
(Tsuchiya et al., 2000). In ATL, 48% of primary samples have
methylated promoter DNA in the APC region (Yang et al., 2005).
The methylated CpG island amplification/representational dif-
ference analysis method revealed 53 aberrantly hypermethylated
DNA sequences in ATL (Yasunaga et al., 2004). Among them,
kruppel-like factor 4 (KLF4) and early growth response 3 (EGR3)
were found to be responsible for apoptotic resistance in ATL cell
lines, implicating that DNA methylation is involved in leukemo-
genesis. Abnormal DNA demethylation may also be involved.
MEL1S, an alternatively spliced form of MEL1, is frequently
expressed in ATL cells because of DNA hypomethylation at an
alternative transcriptional start site. Aberrant MEL1S expression
is associated with dysregulation of TGF-β-mediated signaling
(Yoshida et al., 2004). Thus, altered DNA methylation pattern,
including DNA demethylation, is one of the molecular hallmarks
of ATL linking leukemogenesis to gene transcription control.
Histone modifications such as histone acetylation and spe-
cific methylations confer dynamic exchanges of transcription.
Although a global survey of histone modification in ATL (such
as by ChIP-on-chip analysis) has not been reported, experimental
evidence with epigenetic drugs strongly suggests that epigenetic
reprogramming is the background of the molecular hallmarks of
ATL. Histone deacetylase (HDAC) inhibitors effectively inhibit the
proliferation of several cancers (Spiegel et al., 2012) as well as that
of HTLV-1-infected cell lines and primary ATL samples (Nishioka
et al., 2008). Analysis of signaling cascades suggested that HDAC
inhibition can block nuclear translocation of NF-κB components.
Paradoxically, another study implicated that the HDAC inhibitors
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can actively modulate the NF-κB pathway through RelA acetyla-
tion (Chiechio et al., 2009). Anyway, abnormal histone deacetyla-
tion may be involved in cell survival and cell cycle regulation in
ATL cells.
Histone acetylation and DNA methylation actually cooperate
in regulating a cohort of genes during multiple processes of leuke-
mogenesis. For example, thioredoxin-binding protein-2 (TBP-2)
expression is lost during the transformation step in HTLV-1-
infected T cells (Nishinaka et al., 2004). TBP-2 seems to play a
crucial role in the growth regulation of T cells. Sequential treat-
ment with a DNA methylation inhibitor, 5-Aza-dC, and an HDAC
inhibitor can restore the TBP-2 expression, suggesting that loss of
TBP-2 expression is caused by both DNA methylation and his-
tone deacetylation in transformed infected cell lines (Ahsan et al.,
2006).
Besides acetylation, the N-terminus of histone proteins con-
tains several residues that can be methylated. Integrated histone
modification consequently decides the degrees of chromatin con-
densation and subsequent transcriptional sensitivity. Trimethyla-
tion of the histone H3 Lys27 (H3K27me3) mark plays a central
role in the repression of transcription, mainly in the euchro-
matin region. The Polycomb family is a master regulator of the
H3K27me3 level by inducing and maintaining the histone mark.
Progress over the past decade has defined two main protein
complexes: Polycomb repressive complex 1 (PRC1) and PRC2,
with fundamental roles in Polycomb-mediated gene silencing
(Schuettengruber et al., 2007). PRC2 methylates the histone his-
tone 3 lysine 27 (H3K27). PRC1 is commonly viewed as an
important, direct executor of silencing at target genes. Although
H3K27 methylation is a key chromatin mark, there is ongoing
debate about its molecular consequences. In the context of cancer
research, deregulation by the Polycomb family confers a specific
gene expression pattern responsible for chronic proliferation, sur-
vival, peculiar development, and cancer-associated stemness in
various cancer types, including ATL (Sparmann and van Lohuizen,
2006).
The involvement of the Polycomb family in ATL was first
revealed by global gene expression analysis. Significantly higher
levels of enhancer of zeste homolog 2 (EZH2) as well as RING1
and YY1 binding protein (RYBP) transcripts with enhanced
H3K27me3 levels were found in ATL cells compared with nor-
mal CD4+ T cells (Sasaki et al., 2011). EZH2 serves as the catalytic
subunit in the PRC2 and mediates gene silencing by catalyzing
the trimethylation of H3K27 at the promoters of target genes.
EZH2 is highly expressed in many cancer types, including breast
and prostate cancer and lymphomas, and it is often correlated
with advanced stages of tumor progression and a poor progno-
sis. Importantly, EZH2 inhibition by 3-deazaneplanocin A and
the HDAC inhibitor panobinostat showed a synergistic effect in
killing the ATL cell lines. Because the Polycomb family gener-
ally contributes to silencing of tumor suppressor genes, e.g., the
CDKN2 family, the genes silenced in ATL should be addressed to
elucidate the functional significance of the Polycomb family in the
leukemogenic process.
We recently identified a notable gene silenced by Polycomb.
A human gene that encodes miR-31, hsa-miR-31, is located at
9p21.3, which is adjacent to clusters of the CDKN2 and IFNA
families. In addition to the genetic loss (12.5% of ATL cases), tran-
scription of the miR-31 precursor is completely lost in ATL cells.
Computational predictions and experimental evidence clearly
demonstrated that an assembly of YY1 binding motifs upstream
of the miR-31 region is responsible for the occupancy of the
Polycomb family at the target region, which leads to H3K27me3-
dependent transcriptional repression. Overexpression of EZH2
and suppressor of zeste 12 (SUZ12) homolog, components of
PRC2, in ATL cells can induce and maintain the epigenetic silenc-
ing of miR-31. Of note, given that miR-31 is a master regula-
tor of the ATL-specific gene expression pattern described above,
Polycomb-mediated loss can influence gene expression down-
stream of miR-31 (Figure 4). Indeed, the amount of EZH2 and
SUZ12 directly strengthens cellular miR-31 depletion, which in
turn activates the NF-κB pathway through NIK induction and
confers anti-apoptotic features to T cell (Yamagishi et al., 2012).
It is noteworthy that the molecular and biological interconnec-
tions between Polycomb–miR-31–NF-κB are conserved in breast
cancer cells and B lymphocytes. By organizing the new principle,
various cell types may realize the more complex gene regulatory
network required for maintenance and execution of cellular func-
tions. Imbalance of this network probably switches the cell fate
from one to another.
The origin of epigenetic reprogramming observed in ATL cells
remains elusive. In addition to self-dysfunction of the epige-
netic machinery, a possible mechanism is viral hijacking; HTLV-
1 Tax can physically associate with the key histone modifiers
HDAC1 (Ego et al., 2002), SUV39H1 (Kamoi et al., 2006), and
SMYD3 (Yamamoto et al., 2011). However, at present, the possible
influence of the Tax-epigenetic association on gene regulation is
unknown. Governing the epigenetic system by Tax may disrupt
gene expression, leading to chronic proliferation and abnormal
survival of HTLV-1-infected cells. In the context of viral gene
regulation, epigenetic changes, mainly DNA methylation, in the
HTLV-1 provirus may facilitate ATL cell evasion of the host
immune system by suppressing viral gene transcription (Koiwa
et al., 2002; Taniguchi et al., 2005). Recent studies using in vivo
models strongly suggested that Tax and also other viral proteins
are directly linked to leukemogenesis, despite viral gene expres-
sion being rare in circulating leukemic cells in patients (Hasegawa
et al., 2006; Ohsugi et al., 2007b; Banerjee et al., 2010; Satou et al.,
2011). Furthermore, not only histone methylation but also other
histone modifications such as phosphorylation and ubiquitination
are intriguing for understanding the molecular and physiological
hallmarks of ATL.
THERAPEUTIC TARGETING OF ATL
To establish more effective molecular-targeted therapies for ATL,
we need to understand the exact molecular underpinnings of ATL.
In addition to classical molecular characteristics, the emerging
hallmarks of miRNA deregulation and epigenetic reprogramming
broaden the scope of conceptualization of the responsible mole-
cular mechanism (Figure 4). As highlighted in this review, ATL
possesses six molecular hallmarks: genomic abnormality, specific
changes in gene expression, sustaining activated signaling, produc-
ing cytokines, miRNA deregulation, and epigenetic reprogram-
ming. These molecular hallmarks confer robustness to leukemic
Frontiers in Microbiology | Virology September 2012 | Volume 3 | Article 334 | 10
Yamagishi and Watanabe Molecular hallmarks of adult T cell leukemia
cell hallmark capabilities: resisting cell death, promoting cell cycle,
invasiveness, chronic proliferation, replicating immortality, and
drug resistance (Figure 5). Consideration of hallmark principles
should aid in developing future therapeutics. Several studies with
inhibitory agents have clearly indicated that blockade of signal-
ing drivers appears to be both practical and feasible for inducing
leukemic cell apoptosis. However, common clinical traits of ATL
include relapse and drug resistance. Importantly, each of the core
hallmark capabilities is regulated by a partially redundant sig-
naling pathways. Consequently, a targeted therapeutic agent that
inhibits only one key pathway in ATL may not completely shut
off another hallmark capability, allowing some ATL cells to sur-
vive with residual function until they or their progeny eventually
adapt to the selective pressure imposed by the therapy. In this
case, given that the number of parallel signaling pathways sup-
porting a given hallmark is limited, it may become possible to
target all of these supporting pathways therapeutically, thereby
preventing the development of adaptive resistance. However, it is
possible that this could involve critical side effects. Alternatively,
most upstream elements that can act pleiotropically in leukemic
cells, e.g., miRNA and epigenetics, may be heralded as one of
the fruits of remarkable progress into understanding the ATL
mechanism. Moreover, selective co-targeting of multiple core and
emerging molecular hallmarks in mechanism-guided combina-
tions therapies will result in more effective and durable therapies
for aggressive ATL.
CONCLUSION AND FUTURE DIRECTION
We have explored our present understanding of the molecular
aspects of ATL to refine and extend the six specific traits, the
molecular hallmarks of ATL, which have provided a useful con-
ceptual framework for understanding the complex biology of ATL
(Figure 5).
Other areas are currently in rapid flux. In recent years, the
biological importance of several elaborate ATL models, including
the Tax-transgenic model (Hasegawa et al., 2006), HBZ transgenic
model (Satou et al., 2011), and HTLV-1-infected humanized SCID
mice (Banerjee et al., 2010), has been proposed. ATL-initiating
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microRNA Epigenetic
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activated signaling
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FIGURE 5 | Conceptual illustration of the molecular hallmarks
of ATL.This illustration encompasses the six molecular hallmarks of
ATL. These organized principles provide characteristics of ATL itself.
Because they may be directly associated with the clinical traits of
ATL, targeting the one outstanding hallmark or co-targeting of
multiple molecular hallmarks in mechanism-guided combinations
will result in more effective and durable therapies for
aggressive ATL.
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stem cell theory has also been developed (Yamazaki et al., 2009;
El Hajj et al., 2010). Similar to other lymphomas and solid can-
cers, leukemic cells in tissues may be encompassed by a tumor
microenvironment that contributes to leukemogenesis. The orga-
nized principles of the molecular basis of ATL may be helpful in
the coming decade of ATL study.
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